<SEC-DOCUMENT>0001023024-25-000021.txt : 20250314
<SEC-HEADER>0001023024-25-000021.hdr.sgml : 20250314
<ACCEPTANCE-DATETIME>20250314161025
ACCESSION NUMBER:		0001023024-25-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250314
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250314
DATE AS OF CHANGE:		20250314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANI PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001023024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				582301143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31812
		FILM NUMBER:		25740088

	BUSINESS ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623
		BUSINESS PHONE:		2186343500

	MAIL ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOSANTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19991228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEN ABRAHAM TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19991027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ani-20250314.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:092e0628-394b-4f00-953a-cdb72afe5c60,g:aedb5e41-803f-4770-ba06-7d204b0d9334,d:1a4b2d957646462eb2a9bcfe93eda2e2-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ani-20250314</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001023024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ani-20250314.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-14</xbrli:startDate><xbrli:endDate>2025-03-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1a4b2d957646462eb2a9bcfe93eda2e2_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of Earliest Event Reported): </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 14, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ANI PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-31812</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">58-2301143</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">210 Main Street West</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Baudette</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Minnesota</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">56623</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">218</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">634-3500</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">ANIP</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-16">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-17">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-18">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-19">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging Growth Company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#168;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1a4b2d957646462eb2a9bcfe93eda2e2_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Events </span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;On March 14, 2025, ANI Pharmaceuticals, Inc., issued a press release announcing that the U.S. Food and Drug Administration has approved an expanded label for ILUVIEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</span></div><div id="i1a4b2d957646462eb2a9bcfe93eda2e2_10"></div><div style="-sec-extract:summary;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20250314xexx991.htm">Press Release, dated March 14, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded with the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1a4b2d957646462eb2a9bcfe93eda2e2_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: March 14, 2025</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI PHARMACEUTICALS, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Stephen P. Carey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stephen P. Carey</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President Finance and Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>anip-20250314xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i14caf13c2e5b408eb765ffa6facb7ea6_36"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><img alt="a1a.jpg" src="a1a.jpg" style="height:102px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> Label</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.8pt">ANI plans to begin marketing ILUVIEN in the U.S. under the combined label later this year</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BAUDETTE, Minn.&#8212; (GLOBE NEWSWIRE) &#8211; March 14, 2025 &#8211; ANI Pharmaceuticals, Inc. (Nasdaq&#58; ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The approval also included other updates to the label including to the Warnings and Precautions section. As previously announced, the Company plans to market ILUVIEN for chronic NIU-PS in addition to its current indication of diabetic macular edema (DME) in the U.S. ILUVIEN is already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nikhil Lalwani, Presiden</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t and CEO of ANI stated, &#8220;ILUVIEN&#8217;s expanded label and the strengthening of our partnership with long-standing ILUVIEN contract manufacturer, Seigfried, will enhance supply security and access for appropriate NIU-PS and DME patients in need</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ANI previously announced that it extended its supply agreement for ILUVIEN with a subsidiary of Siegfried Holding AG (Seigfried) through 2029. Siegfried and ANI also agreed to upgrade equipment on the existing manufacturing line and significantly expand capacity. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">INDICATIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ILUVIEN is a corticosteroid indicated for&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:107%">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:107%">CONTRAINDICATIONS</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">ILUVIEN is contraindicated in patients with glaucoma who have cup to disc ratios of greater than 0.8.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WARNINGS AND PRECAUTIONS</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Intravitreal Injection-related Effects&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. For patients with non-infectious uveitis affecting the posterior segment, hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection. Patients may experience temporary blurred vision after injection of the implant.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Intraocular Pressure (IOP) Increase&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Prolonged use of corticosteroids may result in the development of glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be routinely monitored during the course of the treatment.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Cataracts&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Delayed Corneal Wound Healing&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Corneal and Scleral Melting&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of ophthalmic corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation of the globe.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Bacterial Infections&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. Acute purulent or parasitic infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Viral Infections&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution&#59; frequent slit lamp microscopy is recommended.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Fungal Infections&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.8pt">Risk of Implant Migration&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADVERSE REACTIONS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Diabetic Macular Edema</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ocular adverse reactions reported by greater than or equal to 1% of patients in the two combined 3-year clinical trials following injection of ILUVIEN for diabetic macular edema include&#58; cataract (82%), myodesopsia (21%), eye pain (15%), conjunctival hemorrhage (13%), posterior capsule opacification (9%), eye irritation (8%), vitreous detachment (7%), conjunctivitis (4%), corneal oedema (4%), foreign body sensation in eyes (3%), eye pruritus (3%), ocular hyperaemia (3%), optic atrophy (2%), ocular discomfort (2%), photophobia (2%), retinal exudates (2%), anterior chamber cell (2%), and eye discharge (2%). Non-ocular adverse reactions reported by greater than or equal to 5% of patients include&#58; anemia (11%), headache (9%), renal failure (9%), and pneumonia (7%) </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Increased Intraocular Pressure&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 34% of ILUVIEN patients versus 10% of sham patients. IOP elevation greater than or equal to 30 mm Hg was seen in 20% of ILUVIEN patients versus 4% of sham patients. 38% of the patients who received ILUIVEN were subsequently treated with IOP-lowering medications during the study versus 14% of sham patients. 5% of the patients who received ILUIVEN needed surgical intervention for elevated IOP versus 1% of sham patients</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cataracts and Cataract Surgery&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The incidence of cataract development in patients who had a phakic study eye was higher in the ILUVIEN group (82%) compared with Sham (50%). The median time of cataract being reported as an adverse event was approximately 12 months in the ILUVIEN group and 19 months in the Sham group. Among these patients, 80% of ILUVIEN subjects versus 27% of sham-controlled subjects underwent cataract surgery, generally within the first 18 Months (Median Month 15 for both ILUIVEN group and for Sham) of the studies. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ocular adverse reactions reported by greater than or equal to 1% of patients in the three combined clinical trials through 12 months following injection of fluocinolone acetonide intravitreal implant&#58; cataract (56%), visual acuity reduced (15%), macular edema (11%), uveitis (10%), conjunctival hemorrhage (8%), eye pain  (8%), hypotony of eye (7%), anterior chamber inflammation (5%), dry eye (4%), vitreous opacities (4%), conjunctivitis (4%), posterior capsule opacification (4%), ocular hyperemia (4%), vitreous haze (3%), foreign body sensation in eyes (3%), vitritis (3%), vitreous floaters (3%), eye pruritus (3%), conjunctival hyperemia (2%), ocular discomfort (2%), macular fibrosis (2%), glaucoma (2%), photopsia (2%), vitreous hemorrhage (2%), iridocyclitis (1%), eye inflammation (1%), choroiditis (1%), eye irritation (1%), visual field defect (1%), and lacrimation increased (1%). Non-ocular adverse reactions reported by greater than or equal to 2% of patients include&#58; nasopharyngitis (5%), hypertension (3%), and arthralgia (2%). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Increased Intraocular Pressure&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 22% of fluocinolone acetonide patients versus 12% of sham patients. IOP elevation greater than or equal to 30 mm Hg was seen in 12% of fluocinolone acetonide patients versus 3% of sham patients. 43% of the patients who received fluocinolone acetonide were subsequently treated with IOP-lowering medications during the study versus 41% of sham patients. 2% of the patients who received fluocinolone acetonide needed surgical intervention for elevated IOP versus 2% of sham patients.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please see full </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">About ANI</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ANI Pharmaceuticals, Inc. (Nasdaq&#58; ANIP) is a diversified biopharmaceutical company committed to its mission of &#8220;Serving Patients, Improving Lives&#34; by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology&#59; its Generics business, which leverages R&#38;D expertise, operational excellence, and U.S.-based manufacturing&#59; and its Brands business. For more information, visit </font><font style="color:#467886;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">www.anipharmaceuticals.com</font><font style="color:#0a2f41;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Company&#8217;s generic pipeline, 2025 guidance, other statements that are not historical in nature, particularly those that utilize terminology such as &#8220;anticipates,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;future,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;continue,&#8221; other words of similar meaning, derivations of such words and the use of future dates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Uncertainties and risks may cause the Company&#8217;s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to&#58; the ability of our approved products, including Cortrophin Gel, ILUVIEN and YUTIQ, to achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability&#59; our ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, including the acquisition of Alimera, in a timely manner or at all&#59; the limitation of our cash flow as a result of the indebtedness and liabilities incurred from the recent acquisition of Alimera&#59; the risks that our acquisitions and investments, including the recent acquisition of Alimera, could disrupt our business and harm our financial position and operating results&#59; delays and disruptions in production of our approved products, increased costs and potential loss of revenues if we need to change suppliers due to the limited number of suppliers for our raw materials, active pharmaceutical ingredients, expedients, and other materials&#59; delays and disruptions in production of our approved products as a result of our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel, ILUVIEN and YUTIQ&#59; delays or failure in obtaining and maintaining approvals by the FDA of the products we sell&#59; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies, and the focus of the current U.S. presidential administration, including among other things, drug recalls, regulatory approvals, facility inspections and potential enforcement actions&#59; risks that we may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of our products from both domestic and overseas sources due to supply chain disruptions or for any other reason&#59; the ability of our manufacturing partners to meet our product demands and timelines&#59; the impact of changes or fluctuations in exchange rates&#59; our ability to develop, license or acquire, and commercialize new products&#59; our obligations in agreements under which we license, develop or commercialize rights to products or technology from third parties and our ability to maintain such licenses&#59; the level of competition we face and the legal, regulatory and&#47;or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products&#59; our ability to protect our intellectual property rights&#59; the impact of legislative or regulatory reform on the pricing for pharmaceutical products&#59; the impact of any litigation to which we are, or may become, a party&#59; our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries&#59; our ability to maintain the services of our key executives and other personnel&#59; and general business and economic conditions, such as inflationary pressures, geopolitical conditions including but not limited to the conflict between Russia and the Ukraine, the conflict in the Middle East, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies, and other risks and uncertainties that are described in ANI&#8217;s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other periodic reports filed with the Securities and Exchange Commission.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">More detailed information on these and additional factors that could affect the Company&#8217;s actual results are described in the Company&#8217;s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company&#8217;s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor Contact Lisa M. Wilson, In-Site Communications, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">212-452-2793  </font></div><div><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">lwilson&#64;insitecony.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">SOURCE&#58; ANI Pharmaceuticals, Inc.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ani-20250314.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:092e0628-394b-4f00-953a-cdb72afe5c60,g:aedb5e41-803f-4770-ba06-7d204b0d9334-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ani="http://ani.com/20250314" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ani.com/20250314">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ani-20250314_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ani-20250314_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://ani.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ani-20250314_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:092e0628-394b-4f00-953a-cdb72afe5c60,g:aedb5e41-803f-4770-ba06-7d204b0d9334-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_aa25f0f9-8562-4585-936d-12f849cdf96e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7d6fd710-57e9-4c76-a873-2fe56a8c20e1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_73e4ac45-7c11-4b09-aa4c-d656fcdc8793_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_39165e72-b5b2-45bf-bf92-1a08e5cebfb4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cb085a1c-3c83-49fd-99ab-6b672ea4087d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_004e7b0e-2124-4d34-9aae-7e99ab339398_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_db0b9a6d-022f-429c-96b6-431508367049_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f496ccf8-1bf1-469b-ba55-5b1a6c144332_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_79c5b2b5-f12a-4579-a1b0-bcf93fcbb1c2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_877ea7cb-1883-41f5-9496-ffb5da7a365e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f4bb8f07-9186-4989-a10c-860566abc2b1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_dd2fc002-568c-4701-aff9-1415164f388c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6656fb73-994e-48c7-bfc6-df61d0a0485b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c481b2cf-769b-4e91-ae5b-ee023f63277a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ead4dcc9-8c9a-4059-b729-16e93c0e65a7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_672fde95-361a-42d2-88e9-cf3eec8ac0fc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_54853246-d96a-4417-a332-8a252239dad4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e8036b3b-1235-4b13-8f75-99ff8b513cd4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b280999b-2642-475c-9e1a-bc71a818930e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0fd9621f-532f-4a8a-8b79-18c9d04ca922_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e753d1df-1811-4296-b2ee-9bde5e932661_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_193f2752-b63c-4f62-853e-2a73e5231211_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ani-20250314_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:092e0628-394b-4f00-953a-cdb72afe5c60,g:aedb5e41-803f-4770-ba06-7d204b0d9334-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ani.com/role/Cover" xlink:type="simple" xlink:href="ani-20250314.xsd#Cover"/>
  <link:presentationLink xlink:role="http://ani.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_df4bd328-545c-4627-92f7-58ca789c6cf6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_DocumentType_df4bd328-545c-4627-92f7-58ca789c6cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a80e1eee-ea02-44d1-af80-e36c7f4ed6ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_DocumentPeriodEndDate_a80e1eee-ea02-44d1-af80-e36c7f4ed6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_25e08859-29de-4d58-945b-6e5776f97e39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityRegistrantName_25e08859-29de-4d58-945b-6e5776f97e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_644567ce-152a-4f0f-8b10-528060b618aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_644567ce-152a-4f0f-8b10-528060b618aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2ae8734f-fc48-4ff4-8726-a2dadb124a09" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityFileNumber_2ae8734f-fc48-4ff4-8726-a2dadb124a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c358a188-b87e-46d7-bbaa-0eb278fd80f5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityTaxIdentificationNumber_c358a188-b87e-46d7-bbaa-0eb278fd80f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fa10fbb2-808b-4d36-879c-4fd9fc31824a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityAddressAddressLine1_fa10fbb2-808b-4d36-879c-4fd9fc31824a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8c6c075f-95ad-40e1-b930-526a3e06510d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityAddressCityOrTown_8c6c075f-95ad-40e1-b930-526a3e06510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5f67bfbb-fd90-4355-a49f-d7605b45034c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityAddressStateOrProvince_5f67bfbb-fd90-4355-a49f-d7605b45034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_976d26e6-2a8e-4deb-ac71-589970f27189" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityAddressPostalZipCode_976d26e6-2a8e-4deb-ac71-589970f27189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bab7878b-7d14-4969-b90c-7385fbdd5af6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_CityAreaCode_bab7878b-7d14-4969-b90c-7385fbdd5af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ad9792ec-f350-4e09-b74f-7d8ee0583957" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_LocalPhoneNumber_ad9792ec-f350-4e09-b74f-7d8ee0583957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_28682718-738d-40a8-ab9e-296276eb2f34" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_Security12bTitle_28682718-738d-40a8-ab9e-296276eb2f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_363f007c-b574-47a6-bddb-ee10e6f0af9f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_TradingSymbol_363f007c-b574-47a6-bddb-ee10e6f0af9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3fb90f5e-7315-4d68-85bf-6d1f74a409e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_SecurityExchangeName_3fb90f5e-7315-4d68-85bf-6d1f74a409e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_817878aa-5be1-489d-a1b8-ef3e7e2e4091" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_WrittenCommunications_817878aa-5be1-489d-a1b8-ef3e7e2e4091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_60f6d9b6-37cc-43c2-81a2-15359ccebcb5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_SolicitingMaterial_60f6d9b6-37cc-43c2-81a2-15359ccebcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_32aefd7e-a728-428e-b03d-9d46c5e0e124" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_PreCommencementTenderOffer_32aefd7e-a728-428e-b03d-9d46c5e0e124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_61f1fa3c-a6b2-4363-8cfc-531234ee5eb9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_61f1fa3c-a6b2-4363-8cfc-531234ee5eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_69ba0561-97de-47cf-aac1-fd7d2ce39776" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityEmergingGrowthCompany_69ba0561-97de-47cf-aac1-fd7d2ce39776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1ab19671-861e-4865-bb46-fd42c6dc8f22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_EntityCentralIndexKey_1ab19671-861e-4865-bb46-fd42c6dc8f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e3f2a6dd-7b84-4464-b957-a5ba84c2ac93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_abf9d36c-377c-4433-bdf8-1caebae70cd5" xlink:to="loc_dei_AmendmentFlag_e3f2a6dd-7b84-4464-b957-a5ba84c2ac93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a1a.jpg
<TEXT>
begin 644 a1a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F ,H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"<4 +16+J7B
MC2],E,$MU$;G_GB&RWXX!Q^-16_B=+CG[/A?7S,_TKAQ.8X;#-*K.U_ZZ'1'
M"UI1YU%V-^BHH+A+A \9!!J6NN$XSBI0=TS!IIV844458@HHI,B@!:*3(]:,
MCUH 6BC(I,B@!:*,T4 %%%% !11D49H **,TF10 M%&:,B@ HI,BEH 0G KD
M?'_B.;0-&5;5PMU=$QQMGE!CEA^GYUUQZ5\]?&34M1L_'\32HQM1:((%;.TC
M)W$>^?Z5G54G!J.YUX*5&.(A*O\ "GJ94<[I<B=F9GW;F8G)/KDUZ)H5\)80
M<]J\@7Q%:%0624'TP/\ &NF\'Q^*/%=P+71XC9V&_$]\XSL7N%)X+8[#/U'6
MOF,9E57%1Y;6?=GVN99E@9T?<G=]+'O&AP,$\\GY64@#\1S^E;%5K"SBL+*"
MT@W>5#&(UW')P!CD]S[U9KWL#A(X2@J,>A\'4GSR<@K/US6+;0-&N=4O YM[
M9-[^6,MC(' _&M"N.^*C;?AIK9/_ #R4?^/K7:9G/7/QBB=<V&CNRL,JUQ,%
M/XJH/\ZQI_BMK\YVP0646>FV)F/ZG^E<?H.CWNMW%O96,)>5E&3_  H/5CV%
M>Y>&?!.F^'88Y%037NWY[AQDY[[1V%>A.-&DMKL^?HU,9BI.TN6)S&G#XCZW
M LXO8K&%^098D0D>PVD_GBK<GA#QBZEO^$M??Z NH_3_  KT4<"BN5UGT27R
M/46$C;WI-_-GA'B"^\8^$[^&WU'5;H"<'R9DF+QN1U )'7V(%,M_B1XGMV&Z
M]28#M+"IS^0!KNOC)):)X!F2<*;B2XA6TR.1)O!R/^ AJ\9KMP[56+YDM#Q\
M>IX:4?9S>OF>I:1\6RSB/6+%0O>6VSQ]5)_D:]/MYXKF".>%P\<BAD93D$'H
M:^7J]Q^%TLLG@Z,2DE4F=8\_W>O\\UGB:$8+FB=&6XVI5G[.IJ=%KFKG1;$7
M7]G7U\-X4QV40D<<$[L$CCC]17$O\7],^;RM-NVP<89E7!]#UKTAB I)(  Y
MS7S+K-[!JGB?6=2M0/LMS=,8B!@,H 7=^.,UAAX1G+EDCLQ]:=&GSP=F>D2_
M&(#_ %6B$^[W./Y+5"?XNZL_%OI]G&3TW[G_ *BO.Z<D3S.L40<R.0JA/O$G
MICWKT/JU)=#P?[1Q,G9R_!'M&H_$6UT&TMX+[;>:PT8>6WM!A8B>S$D[?3N>
M^.:S%\5^.M9C,VEZ#';VYY5G4EOP9BH/_?-:G@?P!;:#;+=7\,4FH/\ ,.,B
M(>@_VO4_Y/= 8&*\UN$7HKGT$85JD;RERK\?FSPF^\=>,;.[-M>7DUK,/^6<
MEJB$^XRO(]Q42?$7Q0AS_:6[V:&/_P")KL_C3'#_ ,(G9S,J_:4OHE@;ODAL
M@>Q .?I7D5=V'Y*D7>*/'Q_M</-*-1N_F>AZ9\6-4AF4:E:P7$/\1B&QQ^N#
M].*]5TG5+;6=/AOK1BT,JY&1@CU!]Z^9Z]M^%*2+X08OG:URY3/IA1_,&L\5
M1A&/-'0WRW%U:E3V<W='3:[JS:+IK7@L+R]"L 8K2/>X![XST'>O.=8^(_A_
M6K=K:^\.&]C4D;+@K\I[]C@_K7J\C!$9F("@9))X%?-.OZC;ZSXOUG5+0@VL
M\X6)E& X10FX?4@FN?#PC.7+)'?CZLZ-+G@[&M;ZKX/L;D7%GX&MO,!R#<7;
MRJ/^ L"*WF^+.II&([;3;"%5&%!#$ ?0$5Y[6SX7T*3Q#KD%B@Q'G?,W]V,'
MG\^GXUWO#T8*[1X4<=BJDE%2U?DCVWPA?ZKJNBPZAJGDJ\X+)'%&5 7L3DGD
M\GZ$5T%,AB2&)(HU"H@"JHZ #M3Z\F3N[H^JIQ<8I-W85B^)[/2M3T"YL-9N
M5M[&< 2.91'T(8<GW%<#XR^)TRW4VE>'6"F)S'/?G!P1U6,'@GL6/'H#UKS:
MYN;F]G\^[N9KF8_\M)I"[?3)/ ]JZ:6&E/5Z(X,5F-.B^5:L]5TWQ7X)\(6\
MMII37-R"WSO$FXN1T^9L CTQQ39_B_;*?]&TB9_^NDX3^0->4#).!7JW@[X<
M0I"E]KL*RR. T=L3P@_VO4^W:MZE*E37--W//HXK$UY<E%**_(@B^*6L7\A3
M3] $C9^ZI>0C\@*V(=8^(-RH9-#T^%3T,S$?IOS7<6]M!:P+#;PQQ1KP$C4*
M!^ K \<>)$\+^&;F\5A]KD'DVB=VE8<<>@ZGV%<KG%Z1B>I&A52O4JO\$>0>
M.=;U36]833M7^S++I;Y*6N=F]E!Y))R0,?3)KG33(DD52TTK2SR,9)9&.2[D
MY))[T^O5I0Y8[6/E\35]K4;NVNEQT:-)(J*I9F. !W/:OHWPWI(T3P_96 P6
MBC^<^K'EOU)KRWX7Z"-0UF34IX@T%FOR;AP93T_(9/Y5[,2%3<< #J:X<74O
M+D70]O*</RP=5]3@_BMXEFT3PXEA8L$OM38PHW]R/'SM]<$#\?:O%HXUBB5$
M'RJ !6QXJ\1?\)7XJNM2B+?8H1]FM,]T!^9A_O'GZ8K)KHPM+ECS/=G#FF(]
MI4]FMH_F%>B?"_PR+Z].M7'^JM7VPKC[TF.OX9'X_2O/H8I+B:.&)2TDC!%4
M=R3@"OH[P]I*:)H5I8*!F*,;R/XF/+'\\T8JIRQY5U%EF']I4YY;+\S5'2B@
M=*R_$&LP:!H5[JER?W=M&6QG[S?PJ/<G _&O)/JCR7XLZ_'JGB2UT2W;='IH
M,MQCIYK#Y1^"DG_@5</3(S-*TMS=,7N[ES-.YZL[')I]>UAZ?)3L?'8ZO[:L
MVMEHBQ8V<NH7]O9P#,L\BQK]2<5]&Z)I46BZ/:Z?"=R0)MW'JQZD_B237E_P
MIT,W.ISZO*G[JW7RXB>[GJ1]!_Z%7KW05Q8NI>7*NA[&58?D@ZCW?Y'$_%/7
MFT?PC);6[@7FI-]ECYY52/G;\%S^)%>(11+!$D2<*HP*VO&6MMXE\97=\DA:
MRM<VMH,\84_,P^K \^E8]=&$I\L>9[LX,TQ'/4]FMH_F%>R_"W0C8Z-+J<T9
M6:\/R!AC$8Z'\3D_E7F'AO1I->UVUL4^Z[9D/]U!RQ_SW-?1D42Q1K&BA44
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METD>[;YI3'X[?3G-6[_PYK-UXZL_$$+V,:6]B]ML9V8[VR=V-HR 2.,\CTK
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/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45588401011744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 14,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANI PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">58-2301143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 Main Street West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baudette<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">56623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">634-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANIP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001023024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !,@6Y:JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( $R!;EIED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !,@6Y:)!Z;HJT   #X 0
M&@              @ &?$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !,@6Y:99!YDAD!  #/ P  $P              @ &$$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #.$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ani-20250314.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ani.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ani-20250314.htm">ani-20250314.htm</File>
    <File>ani-20250314.xsd</File>
    <File>ani-20250314_lab.xml</File>
    <File>ani-20250314_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ani-20250314.htm": {
   "nsprefix": "ani",
   "nsuri": "http://ani.com/20250314",
   "dts": {
    "inline": {
     "local": [
      "ani-20250314.htm"
     ]
    },
    "schema": {
     "local": [
      "ani-20250314.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ani-20250314_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ani-20250314_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://ani.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ani-20250314.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ani-20250314.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ani.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001023024-25-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001023024-25-000021-xbrl.zip
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M5+:3!6;(.N0-,AD_D2JOC' 3I@!X+L1BH<9#7T5#XX2,[QB0"R#XZI62$4:
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MV&A'&@V,3@.;5'0/L$?B0U[IY>A3+HKRMBB;9NFR8I4\*^[RJGP\*U(Y]?U
MQMR7@!$.($A) )0Q";KUT;P00@E-3$$QT#LR/LL,O%8*OWA-$KIJWBH1K\[$
MG"V3,NXG[L#%L>/P$'6Q@M3"K1.Z)O%' ]K"[";F-F]SA?]]FNIIL6CB?BDO
MRN)'INU,4^YSRJ(4?(P5!)@*H'IIA("@T$](%/L!M:.^6V@<W%?:&Q-ZK6\+
M>4^Y3.D>7@0GK!W\.\"\V]P BGL"CXSO;GO;W.X9;P_L12GK<TVIH]17NS\M
M%G>RO*HO%)1?E-*]CPIH)(1* '&%((@H!\["$$*.6"10$!""3:'=)W9D<+4\
MB U];YF M\S :U(P9W=OY?;S>\AZV#$\J!16&)MZ=$)Y;_#1<#:UN8FT\7OL
ML5[?O?)TP?8W_8$QC:D(.>8A*(09!&%,@2'N Q>*$B4X1\*8Y4Z%(P/\=$_.
M4M33JEXM:PYM=UWVDSK8K1V>UD:MD-QIQHG#[HBCP;?3T"9QNP?:8W96_)#E
M>[ZH2B8J@VG4&G^\Z=/(>/]9"_WW,-.F,WFGZ=*.--HTZ32P.3VZ![AV01_F
MLKS.\NM_EL5]=:,_Z6]9_CA-XEBR6'! 27U&B%0(5&^Q0"D>IBQF) J-[Z38
MH3-.#[26]I;:WDK<M@'JKI1I_S/8OU/[8VO=H??9:6Q Z],==^3.9Z>Y[<9G
M]_#!?4^[X^$\47X,%"41!#2I=TF^@"3RPRAB7&!N?"=&O\S8O<Y!FIQ![<W/
M:6R.WM$<J9?Y?^AB[/J7PW0NE\4L$UFE4?]=[\W*C,VF:8J5\'T,890("&(?
M 5.* @I0B*) D201QO=P;(4_,HC/@MY:T>(.CNUB[,=NF$4[W&S<V=W!T6O"
M[1Z.[7#CW<71:Z5U'T?_*(>^I#XJ+"5KKA)%]:U./"9 :2 A2$0,7(D(4A6A
MU&=^D(3<%)_-P$<&YZPY9-9:EA?.6MX-6C)'1Y8=F9D9NWZL(W.W=FPST'C=
M6$?ZK6:LZ_6!5Z0NBD7%9O_.;IO)(8($<2P4Q/6I=B"I7E=DR$%*71T5$1S'
MS.EZ5$MFY*M12VU/BSM=<.XLE&DG-M2^4R-F[=S]*E2GL>'7H-IA?\X5J$YK
MO=>?ND>['U-?Z;=.)4N#5 @*B: , C^DP&.LMWF1I$3X,@I9;'LZ70<>ZU"Z
MUK(_B6ZLFQ] VQIR/'?>Z<7IL'DS\4%GS$V@T8^6-]/O.E%NO6X/PGL=(ZWC
M?)RQZVD48Y5*&@*)D"8!IQB21%(0BD@I$B9\9=SPM"(?&84G+:\6,V>A[7X_
M#,Z>[&@PM&.%0V?J3CRT(XT&1*>!32*Z![ANW,YTH)+-/N6I?/B7?)R&NELA
M.-#="XTT&@&*@1&B^6 XQ)C05"\B=GNV%PKC;-=6HEZCZFE9VWW:R[J8;M$&
MN'7:G9D;==B6]9@9L"-[&7'DS5B/H>U]6-] 5\P^9K/UEQUDXI.($PX(DQ "
MC@@D*@Z!4J42'B(B; E[#CX.7+6>]9<^MNI@2I2;.R>83(PY8+3M8 !!&\%&
MAF?;QC8W'6,&'BG4QQ1?RJOB/I]RG/B44@XX"C $<2B 2KV!XR)&+$$));[E
MI=TMC9$/$YICJZ+T:FG'DX2-^E@>([BY'G:&8&38_0!AV]+PTX.-F#_GZ&#;
M5.^Y0<=05_RNV,.G5*^"F5I](W_UL>TKO3/$2('>)BH(6,(@X3$%E B:^H%@
M%!O?X[93:1P4M;C75G=<V?KJ90KE :K@A*9] 1SPW&-N *1]D4=&=8_!;6#W
MO6'@JKGZ[SS+)9K*."0I2I5FM/Z./J81<"PE4)[*4%*"H\CXAHM>E9%7SM4#
MK];VON2NY_"M.EFNGZ[NAZV@QL;=5]$N8\/7T5;4G[.2=AGK74L[![MB^55>
M9_5MCWG5_.$51(G"<8B!1T1 H"(,24@D8!83&6*",+(DLBTP#HS/FI9_C*:S
M)J;TN3MU L_4I -NW4X&D/8BX,B0==O9YJMG7!]:FQ77,'X_?;5^)EO^M<K3
M5_\#4$L#!!0    ( $R!;EI_/TFOGP8  ,LP   4    86YI+3(P,C4P,S$T
M7W!R92YX;6S5FEMOV\82Q]_S*734US/6WB]&[,+'30Z,XS9&XJ)%7X2]S%I$
M*=*@Z-C^]F=)6TD<.REA"C#SH@NURYGYSX_#W1%?_WRS+F<?L=D4=74PIWMD
M/L,JU+&H+@[FOY^_!3/_^?#5J]?_ OCS/^]/9[_4X6J-53L[;M"U&&?71;N:
MM2N<_5$W?Q<?W>RL=&VJFS7 83_MN+Z\;8J+53MCA,GML.VOS3ZQ#(EB!K@5
M'D0B!*SD#D+TFKF$,BCR[XM]A]%+%!0,X0F$U@2\(PIT9$1X$BWGHC]I651_
M[W<OWFUPEL.K-OW7@_FJ;2_W%XOKZ^N]&]^4>W5SL6"$\,5V]/Q^^,VC\=>\
M'TVMM8O^UT]#-\53 _-IZ>+/7T\_A!6N'135IG55Z QLBOU-?_"T#J[M5?]'
MOV;?'-%]@^TPZ X!9<#IWLTFS@]?S69W<C1UB>\QS;KWW]^??#+IJF(OU.M%
M=WQQ7&<.LH?]C/;V$@_FFV)]6>+VV*K!=##/<Z#+).%4=&9^NINW^&SMLL%-
M1J2/[C0?N)_>&1EL&6]:K"+>!;$]<5F'!X/*3L+ZT\S2>2S[H\N(Q;(_ZY'?
MM(T+[=+Y9"-7 ;C6 83@''Q,!FAPZ!UJ$J)\&&CGZ2:[VBN^P;!W47]<Y!-G
MY1GO/G0R\%Z"1^;NY'B>W]M+[#R/7<8D?.3YZI!"9K<5TV!9TB!-<-K8H$)2
MH]S^TMI#K[],XU$39G43L<DU8FO.->%!2A_3>3]B<>F:?"((JZ*,V]FIJ=>[
MR%5;[T"YN[1D=^>S''7"IL%X>I>5;P;71];FRHG]R%UD_ R;HHYOJOA++JU+
M9PA21 1TA&45(@67# ',RN@D,"J'.TG] [.#&&#39^#Y6KXP#&^JMFAOW^-%
MT2E1M;^Y-2Z91&*,M,!L1!!1&K!">E HM5;):N1V% M/61V$ I\N"J.5G 0)
M)WDYUES632_\AZP_'M=75=O<'M<1ETH(J71 H)*Y;O64P'A*0#)#%/&*&N=V
M ,9WG1C$B9@Z)[O3>1+8O"U*_.UJ[;%9,H=&<Y$@!6&R[TF T4R!8]%%3YEP
M9!?%X[/%04#(J0/Q3 4GD?US=W,2LU9%*NYV&?>!!"Z-H\: -SI7/Q4U>.\<
M$/1,FQ0-2>-6P=\U/X@+-74N=J'M)" YBC&G8'/_EG=J2)?)49*\9WF;;?)N
M/*N42;=9I!1M"IR:S/H. 'G"]" X]-3A&*OIE, XSA_?->?U=;4T>;M$M$Q@
MI8L@\F(:O.7=[4\YCD1)2N+NL/AL>! 4Y@>!XIEZ3@F)?EWTKCEKZH]%%7 I
MD](^LPT990*"2PE.V 11*R*]D(2+L#LNOK(^" [[@\ Q1MDI$7)6;UI7_E5<
M]LMFJU5D"A4P9[K=%GIP05.0QEI-$M/4[&+I^93M8<TL\H/@\7Q97QB.KN@=
M->AZO[WSVNA\$]21"A!6V5SV2 #-C4P^1NE&=C._M#8,@ FW,Y\MW0NGO/MG
MHSQ;U=5V^^2BU99A@,1EKF5(LN\Z[Z9T-(A$&FZE'I7VKRT.2_V$NYBC)'SA
M]'_ <-5D="GSYT5;XI(99;J2U+':+7:< ><M K.*:95W1XF+4>G_VN*P]$^X
M<SE*PA=._WGCNG^//]RN?5TNN>*)D!R\ESJ7+>U45B!Z0*0$52(NV30J]P_,
M#4O\A%N1SQ=O(A?]FYNP<M4%]KUVGO(M*DG,U%*9ERG*@)$^@8HT:>$$L3BN
M[C]E=1@#$^X^CI;RA5'X(SO?8G5<K]=7U7V+;+,TM%N^. ?2Y\VN,#:"H]X
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M+E@^BH('YH9E?\)=R.>+M[.LOUX\$N\T'SA\=?]#]](]^W[XZO]02P,$%
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M$S7US(IH56<QT.E!?[B?%_=$JY]V?#\\W1^-GM\KOG[9(1ZV=F:X/:"=\.Q
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M#%0^!!)^YM\=NWKS[O)X7"4/=.<8/')9_"/_#<8?Z6\__A]02P$"% ,4
M" !,@6Y:$2L5/^ .  "::P  $               @ $     86YI+3(P,C4P
M,S$T+FAT;5!+ 0(4 Q0    ( $R!;EKKIDLH7 (  -L&   0
M  "  0X/  !A;FDM,C R-3 S,30N>'-D4$L! A0#%     @ 3(%N6B490Q[_
M"0  ?50  !0              ( !F!$  &%N:2TR,#(U,#,Q-%]L86(N>&UL
M4$L! A0#%     @ 3(%N6G\_2:^?!@  RS   !0              ( !R1L
M &%N:2TR,#(U,#,Q-%]P<F4N>&UL4$L! A0#%     @ 3(%N6H-26<Q$&0
M G(  !@              ( !FB(  &%N:7 M,C R-3 S,31X97AX.3DQ+FAT
7;5!+!08     !0 % $8!   4/      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ani-20250314_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ani-20250314.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001023024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-03-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ANI PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-31812</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">58-2301143</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">210 Main Street West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Baudette</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">56623</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">218</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">634-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">ANIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
